Clinical Trials Directory

Trials / Completed

CompletedNCT00053547

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
28 (planned)
Sponsor
Abbott · Industry
Sex
All
Age
2 Years – 20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

Conditions

Interventions

TypeNameDescription
DRUGparicalcitol injection

Timeline

Start date
2002-01-01
First posted
2003-02-03
Last updated
2006-08-02

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00053547. Inclusion in this directory is not an endorsement.

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis (NCT00053547) · Clinical Trials Directory